benzofurans and Chagas-Disease

Despite affecting around 8 million people worldwide and representing an economic burden above $7 billion/ year, currently approved medications to treat Chagas disease are still limited to two drugs, nifurtimox and benznidazole, which were developed more than 40 years ago and present important efficacy and safety limitations. Drug repositioning (i.e. finding second or further therapeutic indications for known drugs) has raised considerable interest within the international drug development community. There are many explanations to the current interest on drug repositioning including the possibility to partially circumvent clinical trials and the consequent saving in time and resources. It has been suggested as a particular attractive approach for the development of novel therapeutics for neglected diseases, which are usually driven by public or non-profit organizations. Here we review current computer-guided approaches to drug repositioning and reports on drug repositioning stories oriented to Chagas disease, with a focus on computer-guided drug repositioning campaigns.

Topics: Benzofurans; Chagas Disease; Computational Biology; Drug Repositioning; High-Throughput Screening Assays; Humans; Trypanocidal Agents; Trypanosoma cruzi

Chagas disease is a neglected tropical affection caused by the protozoan parasite Trypanosoma cruzi. There is no current effective treatment since the only two available drugs have a limited efficacy and produce side effects. Thus, investigation efforts have been directed to the identification of new drug leads. In this context, Ca

Topics: Amiodarone; Animals; Benzofurans; Calcium; Chagas Disease; Chlorocebus aethiops; Dose-Response Relationship, Drug; Dronedarone; Inhibitory Concentration 50; Membrane Potential, Mitochondrial; Mitochondria; Oxidoreductases; Trypanocidal Agents; Trypanosoma cruzi; Vero Cells

We report herein a straightforward and efficient one-step reaction to prepare new nor-β-lapachone derivatives tethered with phenylthio groups at position 3 of the furan ring. We have screened the compounds on bloodstream trypomastigotes of Trypanosoma cruzi, the causative agent of Chagas disease, aimed at finding a new prototype with high trypanocidal activity. The new compounds possess a broad range of activity (IC50/24h from 9.2 to 182.7 μM), higher than the original quinone (391.5 μM) and four of them higher than standard drug benznidazole (103.6 μM). The most active was compound 13b (9.2 μM), being 11 times active than benznidazole and the less toxic derivative to heart muscle cells.

Topics: Animals; Benzofurans; Cell Survival; Cells, Cultured; Chagas Disease; Embryo, Mammalian; Heart; Humans; Mice; Myocardium; Naphthoquinones; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma cruzi

Our group assays natural products that are less toxic and more effective than available nitroheterocycles as promising therapeutic options for patients with Chagas disease. Our previous study reported the trypanocidal activity of eupomatenoid-5, a neolignan isolated from the leaves of Piper regnellii var. pallescens, against the three main parasitic forms of Trypanosoma cruzi. The present study further characterizes the biochemical and morphological alterations induced by this compound to elucidate the mechanisms of action involved in the cell death of T. cruzi. We show that eupomatenoid-5 induced oxidative imbalance in the three parasitic forms, especially trypomastigotes, reflected by a decrease in the activity of trypanothione reductase and increase in the formation of reactive oxygen species (ROS). A reduction of mitochondrial membrane potential was then triggered, further impairing the cell redox system through the production of more ROS and reactive nitrogen species. Altogether, these effects led to oxidative stress, reflected by lipid peroxidation and DNA fragmentation. These alterations are key events in the induction of parasite death through various pathways, including apoptosis, necrosis, and autophagy.

Topics: Benzofurans; Cell Death; Chagas Disease; Free Radicals; Humans; Membrane Potential, Mitochondrial; Mitochondria; NADH, NADPH Oxidoreductases; Oxidative Stress; Phenols; Piper; Plant Extracts; Plant Leaves; Reactive Oxygen Species; Trypanosoma cruzi

Because of its severe side effects and variable efficacy, the current treatment for Chagas disease is unsatisfactory. Natural compounds are good alternative chemotherapeutic agents for the treatment of this infection. Recently, our group reported the antiproliferative activity and morphological alterations in epimastigotes and intracellular amastigotes of Trypanosoma cruzi treated with eupomatenoid-5, a neolignan isolated from leaves of Piper regnellii var. pallescens. Here, we demonstrate that eupomatenoid-5 exhibited activity against trypomastigotes, the infective form of T. cruzi (EC₅₀ 40.5 μM), leading to ultrastructural alteration and lipoperoxidation in the cell membrane. Additionally, eupomatenoid-5 induced depolarization of the mitochondrial membrane, lipoperoxidation and increased G6PD activity in epimastigotes of T. cruzi. These findings support the possibility that different mechanisms may be targeted, according to the form of the parasite, and that the plasma membrane and mitochondria are the structures that are most affected in trypomastigotes and epimastigotes, respectively. Thus, the trypanocidal action of eupomatenoid-5 may be associated with mitochondrial dysfunction and oxidative damage, which can trigger destructive effects on biological molecules of T. cruzi, leading to parasite death.

Topics: Benzofurans; Chagas Disease; Glucose-6-Phosphate; Humans; Hydrogen Peroxide; Lignans; Lipid Peroxidation; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Membranes; Oxidative Stress; Phenols; Phosphogluconate Dehydrogenase; Piper; Plant Extracts; Plant Leaves; Trypanocidal Agents; Trypanosoma cruzi

Trypanosoma cruzi is the ethiological agent for Chagas disease in Latin America. This study aimed to test the trypanocidal effect of licarin A and burchellin isolated from plants in northeastern Brazil. These neolignans were tested on T. cruzi and on peritoneal macrophages, to evaluate drug toxicity. Epimastigote growth was inhibited in 45% with licarin A and 20% with burchellin with an IC(50)/96 h of 462.7 microM and 756 microM, respectively. Epimastigotes treated with licarin A presented swollen mitochondria and disorganized mitochondrial cristae, kDNA and Golgi complex. When treated with burchellin, they presented enormous autophagosomes and chromatin disorganization. Licarin A and burchellin were able to induce trypomastigote death with IC(50)/24 h of 960 microM and 520 microM, respectively. Although licarin A presented an IC(50) for trypomastigotes higher than for epimastigotes, both substances acted as therapeutic trypanocidal agents, because they were able to kill parasites without affecting macrophages. Due to our results, burchellin and licarin A need to be further analysed to observe if they may be used as alternative blood additive prophylaxis against Chagas disease, since it has been established that blood transfusion is an important mechanism in the transmission process.

Topics: Animals; Benzofurans; Blood Transfusion; Brazil; Cell Survival; Chagas Disease; Humans; Inhibitory Concentration 50; Lignans; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Plant Extracts; Trypanocidal Agents; Trypanosoma cruzi

The neolignan, burchellin, a natural compound that reduces urine excretion in larvae of the bloodsucking bug, Rhodnius prolixus, a vector of Chagas' disease, is rapidly degraded in the hemolymph of the insect. The main product that accumulates in this tissue has been shown to be piperonyl alcohol. Other catabolites have been identified by GC-MS analysis.

Topics: Animals; Benzofurans; Benzyl Alcohols; Chagas Disease; Hemolymph; Lauraceae; Pesticides; Plant Extracts; Rhodnius; Structure-Activity Relationship

Supplementation of blood with the neolignan burchellin (50 microg/ml), a compound from the arboreous Lauraceae Aniba burchelli, affected the ingestion of blood and the course of excretion of fourth- and fifth-instar larvae of Triatoma infestans, the latter especially within the first 4 h after feeding. The total resultant weight loss of treated fourth instars within 24 and 48 h after feeding was only 24% and 28% vs 41% and 48%, respectively, in untreated bugs. In fifth instars, the total weight losses of untreated bugs within 24 and 48 h after feeding were 38% and 41% whereas the weight of treated bugs decreased by 28% and 34%, respectively. In a treatment of Trypanosoma cruzi-infected fourth instars, burchellin significantly reduced the population density of the established infection in the rectum at 5 and 10 days after feeding. This was especially due to a significant increase in the number of the main dividing stage, the epimastigote.

Topics: Animals; Benzofurans; Chagas Disease; Feeding Behavior; Host-Parasite Interactions; Insect Vectors; Lauraceae; Mice; Population Density; Triatoma; Trypanosoma cruzi

Topics: Administration, Oral; Animals; Benzofurans; Chagas Disease; Female; Mice; Nifurtimox; Nitrofurans; Trypanocidal Agents